No price history available.

Based on consensus from external analysts. Not Kvantra's opinion.

iAnthus Capital Holdings, Inc. is a U.S.-based cannabis enterprise that holds licenses for and actively manages cannabis cultivation, processing, and retail dispensary operations. Its diverse product portfolio encompasses both cannabis and cannabidiol (CBD) offerings. For cannabis, these include traditional biomass items like pre-rolls, various infused products such as edibles and topical creams, and a wide array of concentrates and vapeables, specifically live resins, waxes, oils, tinctures, and vape cartridges. The CBD line features topical creams, tinctures, and sprays, alongside a comprehensive range of beauty and skincare solutions, including lotions, haircare items, lip balms, and bath bombs. Beyond direct retail, the company also engages in wholesale distribution of its CBD product selection. Operationally, iAnthus maintains a significant presence, controlling or operating 32 retail dispensaries and 10 cultivation or processing facilities across eight states. Established in 2014, its corporate headquarters are located in New York, New York.

• Tianda Pharmaceuticals Limited
• Aytu BioPharma, Inc.
• Shenzhen Neptunus Interlong Bio-technique Company Limited
• MariMed Inc.
• TherapeuticsMD, Inc.
• C21 Investments Inc.
• Rubicon Organics Inc.
• Rockwell Medical, Inc.